(1) Publication number:

0 268 990 **A3** 

(12)

## **EUROPEAN PATENT APPLICATION**

21) Application number: 87117019.7

② Date of filing: 18.11.87

(1) Int. Cl.4: C07D 285/24, C07D 417/04, A61K 31/54, C07C 143/80

Priority: 21.11.86 GB 8627857 22.06.87 GB 8714598 02.09.87 GB 8720659

43 Date of publication of application: 01.06.88 Bulletin 88/22

 Designated Contracting States: AT BE CH DE ES FR GB GR IT LI LU NL SE

Box Date of deferred publication of the search report: 10.08.88 Bulletin 88/32

(71) Applicant: Fujisawa Pharmaceutical Co., Ltd. 3, Doshomachi 4-chome Higashi-ku Osaka-shi, Osaka 541(JP)

2 Inventor: Oku, Teruo No. 2-17-1, Umezono Sakuramura Niihari-gun Ibaraki 305(JP) Inventor: Todo, Eishiro No. 2-15-2-301, Umezono Sakuramura

Niihari-gun Ibaraki 305(JP) Inventor: Kasahara, Chiyoshi

No. 2-15-2-501, Umezono Sakuramura

Niihari-gun Ibaraki 305(JP) Inventor: Nakamura, Katsuya No. 9-6-307, inarimae Yatabemachi Tsukuba-gun Ibaraki 305(JP)

Inventor: Kayakiri, Hiroshi No. 2-5-4-506, Umezono Sakuramura

Niihari-gun Ibaraki 305(JP) Inventor: Hashimoto, Masashi

No. 2-11-6-408, Takezono Sakuramura

Niihari-gun Ibaraki 305(JP)

(4) Representative: Türk, Gille, Hrabal Bruckner Strasse 20 D-4000 Düsseldorf 13(DE)

Mew benzothiadiazine compounds, processes for the preparation thereof and pharmaceutical composition comprising the same.

◀⑤ A compound of the formula:

wherein R1 is phenyl, lower alkyl, or heterocyclic

group which may be substituted, or cyclo(lower)alkyl;

A is lower alkylene,

n is an integer of 0 or 1,

R2 is hydrogen or lower alkyl,

R<sup>3</sup> is hydrogen; hydroxy, halogen; halo(lower)-alkyl; lower alkyl; lower alkylamino; acylamino; acyl(lower)alkylamino; lower alkoxy, cyclo(lower)alkyl, or cyclo-(lower)alkyloxy which may have certain substituents;

R4 is hydrogen or halogen, and

R<sup>5</sup> is hydrogen or halogen,

provided that

R¹ is phenyl substituted with lower alkoxy, lower alkylamino, lower alkylthio, aryloxy, carboxy, esterified carboxy, carboxy(lower)alkyl or esterified carboxy(lower)alkyl;

lower alkyl substituted with carboxy or esterified carboxy;

or heterocyclic group substituted with lower alkyl, when R³ is hydrogen or halogen, and pharmaceutically acceptable salt thereof,

processes for their preparation and pharmaceutical compositions comprising them. The invention also relates to intermediate compounds of the formula



## **EUROPEAN SEARCH REPORT**

EP 87 11 7019

-		IDERED TO BE RELEVA		CLASSIFICATION OF THE	
Category		h indication, where appropriate, ant passages	Relevant to claim	APPLICATION (Int. Cl.4)	
Х .	CH-A-460 032 (R. * Whole document		1-6.8.	C 07 D 285/24 C 07 D 417/04	
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		9	A 61 K 31/54 C 07 C 143/80	
x	DE-B-1 067 028 (	BAYER)		C 07 C 143/80	
	* Whole document column 3, line		1-6,8, 9		
X	IL FARMACO, edizi vol. 34, no. 3, 199-210 L. RAFFA et al.:	March 1979, pages			
		possibile azione	-		
	,	especially page page 201, table	* 1-6,8, 9	-	
A 	CHEMICAL ABSTRACTS, vol. 67, n 1, 3rd July 1967, page 156, abstract no. 1740m Columbus, Ohio, US;		1-9	TECHNICAL FIELDS SEARCHED (Int. Cl.4)	
				C 07 D 285/00 C 07 D 417/00	
	P. ROYER et al.: hypercalciuria w renal injury in & ACTUAL. NEPHRO 1966, 245-64.	ith nanism and children",			
			'		
		-			
1					
	MANAGEMENT AND MANAGE	**************************************			
<del></del>	Place of search	Date of completion of the searc	h	Examiner	
THE	HAGUE	25-02-1988	ALL	ALLARD	
Y : pa	CATEGORY OF CITED DOCL articularly relevant if taken alone articularly relevant if combined w ocument of the same category	E: earlier; after the with another D: docume	or principle under patent document, e filing date ent cited in the ap ent cited for other	lying the invention but published on, or plication reasons	
0 : no	chnological background on-written disclosure termediate document	&: membe docume	r of the same pate ent	ent family, corresponding	

	CLA	IMS INCURRING FEES			
The	oracant	European patent application comprised at the time of filing more than ten claims.			
1116					
	Ш	All claims fees have been paid within the prescribed time limit. The present European search report has been drawn up for all claims.			
	П	Only part of the claims fees have been paid within the prescribed time limit. The present European search			
		report has been drawn up for the first ten claims and for those claims for which claims fees have been paid,			
		namely claims:			
		No claims fees have been paid within the prescribed time limit. The present European search report has been			
		drawn up for the first ten claims.			
	LA	CK OF UNITY OF INVENTION			
The	Search	Division considers that the present European patent application does not comply with the requirement of unity of			
1	ntion an lelv:	d relates to several inventions or groups of inventions,			
	•				
1	. Cl	aims 1-9: 3-oxo-benzothiadiazines, their preparation and use			
2	2. Claim 10: Amino benzenesulphonamides not containing the characteristic structure				
		· · · · · · · · · · · · · · · · · · ·			
	•				
		All further search fees have been paid within the fixed time limit. The present European search report has been drawn up for all claims.			
		Only part of the further search fees have been paid within the fixed time limit. The present European search			
		report has been drawn up for those parts of the European patent application which relate to the inventions in respect of which search fees have been paid.			
		namely claims:			
	×	None of the further search fees has been paid within the fixed time limit. The present European search report			
		has been drawn up for those parts of the European patent application which relate to the invention first mentioned in the claims,			
		namely claims: 1-9			